Study 4 of 4Thymosin Beta-4 (Tβ4) literatureBMJ (Clinical research ed.) · Phase 3Top journal2025
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.
Not reported in abstract.
Where it sits
this study against the rest of the thymosin beta-4 (tβ4) corpus2
Preclinical · this one
2
Observational
0
Open-label
0
Randomised
0
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.20). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Phase 32025
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Thymosin Beta-4 (Tβ4) corpus
CIdentification of Thymosin β4 as an effector of Hand1-mediated vascular development.Nature communications · 2010 · Not reported in abstract.AnimalC[Thymosin β4 inhibits pyroptosis in BV2 microglial cells: a mechanistic study in vitro].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026 · Not reported in abstract.In vitroBThymosin Beta 4 as an Early Biomarker in Sepsis Induced Acute Kidney Injurybiorxiv-preprint · 2021 · n=100 · Not reported in abstract.Human